相关实验视频

Updated: Jun 9, 2025

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

伊马替尼甲酸在患有慢性髓性白血病的患者中引起潜在的心脏功能障碍:一个病例对照研究的结果

Gowri Shankar¹, Ankur Jain², Ankur Gupta³

¹Department of Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

|October 29, 2024

概括

慢性髓性白血病 (CML) 患者的伊马替尼布治疗可能会导致潜在的心脏功能障碍,由左下心室喷射率和变化的减速时间表明. 需要进一步的大规模研究来证实这些心血管影响.

科学领域:

心脏病学心脏病学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

与较新的药物相比,铁氨酸激酶抑制剂伊马替尼的心血管 (CV) 影响仍在争论中.
用伊马替尼布治疗的慢性髓性白血病 (CML) 患者需要仔细监测潜在的不良影响.
非侵入性回声心脏学是评估心脏功能的一个有价值的工具.

研究的目的:

评估伊马替尼在CML患者的心血管效应.
为了比较imatinib-naïve和imatinib治疗的CML患者之间的心声学参数.

主要方法:

一项涉及110名北印度慢性肺炎患者 (≥13年) 的病例控制研究.
患者被分为以前未接受过治疗 (n=35) 和接受过意马替尼 (n=75) 的两组.
2D心声学用于测量肺动脉静脉压 (PASP),左心室喷射率 (LVEF) 和减速时间 (DT).

主要成果:

在接受治疗 (25 mm Hg) 和未接受治疗 (23 mm Hg) 组之间的PASP中位数没有显著差异 (p=0.919).
与未接受治疗组 (61.72%) (p=0.577) 相比,接受治疗组的LVEF中位数较低 (58.5%).
接受治疗组的DT中位数 (204毫秒) 比未接受治疗组的DT中位数 (211毫秒) 更短 (p=0.411).

结论:

伊马替尼布治疗可能与CML患者的潜在心脏功能障碍有关.
研究结果表明,可能会出现降低LVEF和改变透缩功能的趋势.
需要进行大规模的前性后续试验来验证这些初步发现.

关键词:

慢性骨髓性白血病慢性骨髓性白血病伊马替尼布 (Imatinib) 的使用情况左心室透静功能障碍左心室透静功能障碍左心室的缩性功能障碍是什么肺高血压是因为肺高血压.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Myocarditis I: Introduction

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...